Damora Therapeutics is expected to report zero revenue for the third quarter of 2026 and a consensus EPS loss of $0.48, while the current stock price of $21.60 trades significantly below the average analyst target of $46.89.
The primary story for this report is the clinical progress of DMR-001, specifically enrollment and safety updates from the Phase 1/1b CLARITY-101 trial for mutant calreticulin-driven blood disorders.
Following its rebranding from Galecto, Damora is focused on the precision medicine market for hematologic cancers, potentially worth $5 billion. Investors are also weighing competitive threats from Incyte, making management’s commentary on differentiation and its cash runway—expected to fund operations into 2029—critically important.